^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PDE3 inhibitor

    Related drugs:
    1d
    Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov)
    P2, N=50, Recruiting, Haisco Pharmaceutical Group Co., Ltd. | Active, not recruiting --> Recruiting
    Enrollment open
    3d
    Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in COPD (clinicaltrials.gov)
    P3, N=300, Not yet recruiting, Haisco Pharmaceutical Group Co., Ltd.
    New P3 trial
    8d
    TAM-AMIN-UAS: Tamsulosin and Intraureteral Aminophylline for Ureteral Access During RIRS (clinicaltrials.gov)
    P2, N=322, Recruiting, Beni-Suef University
    New P2 trial
    9d
    Intravesical Aminophylline for Urgent Ureteral Stenting in Acute Calculous Anuria (clinicaltrials.gov)
    P2, N=72, Recruiting, Beni-Suef University
    New P2 trial
    9d
    Intravesical Aminophylline to Facilitate Ureteroscopic Access in Children With Distal Ureteral Stones. (clinicaltrials.gov)
    P2, N=60, Recruiting, Beni-Suef University
    New P2 trial
    15d
    Cilostazol inhibits TGF-α-induced migration of hepatocellular carcinoma cells by activating PPARγ. (PubMed, Biochem Biophys Res Commun)
    We also found that PPARγ activators, ciglitazone and pioglitazone, significantly inhibited the TGF-α-induced migration of HuH7 cells. Cilostazol and dipyridamole also inhibited the activation of AKT but not EGFR. Taken together, these results strongly suggest that cilostazol and dipyridamole inhibit TGF-α-induced HCC cell migration by suppressing the AKT pathway through PPARγ activation.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • PPARG (Peroxisome Proliferator Activated Receptor Gamma)
    24d
    Neuroinflammatory and Synaptic Roles of Glial Cells in Autism Spectrum Disorder. (PubMed, CNS Neurol Disord Drug Targets)
    Interventions to correct glial dysfunction-e.g., anti-inflammatory medication (e.g., minocycline, ibudilast), gene therapy, and stem cell therapy-are investigated for their potential to restore glia to normal and diminish ASD symptoms. Understanding glial-neuronal communication mechanisms and their role in neuroinflammation offers a hopeful future for accurate, target-specific treatment. Advances in the elucidation of these processes will foretell an enormous increase in therapeutic efficacy and quality of life for individuals with ASD.
    Journal • IO biomarker
    |
    IL6 (Interleukin 6)
    |
    Eyevinal (ibudilast) • minocycline
    26d
    Relying on Pharmacotherapy to Improve Motor Gains in Chronic Stroke Survivors (clinicaltrials.gov)
    P1, N=50, Not yet recruiting, Spaulding Rehabilitation Hospital
    New P1 trial
    |
    metformin
    28d
    Comparison Between Levosimendan and Adrenaline in CABG Patients (clinicaltrials.gov)
    P=N/A, N=60, Completed, Assiut University | Not yet recruiting --> Completed
    Trial completion
    28d
    A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD (clinicaltrials.gov)
    P3, N=376, Not yet recruiting, Haisco Pharmaceutical Group Co., Ltd.
    New P3 trial
    1m
    WEANLESS: Shorter Weaning From Invasive Ventilation With Levosimendan (clinicaltrials.gov)
    P4, N=250, Recruiting, Radboud University Medical Center
    Trial initiation date
    1m
    A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis (clinicaltrials.gov)
    P2, N=284, Recruiting, Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | N=180 --> 284 | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2026 --> Sep 2027
    Enrollment change • Trial completion date • Trial primary completion date